Journal article

A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer

M Michael, J Zalcberg, P Gibbs, L Lipton, M Gouillou, M Jefford, G McArthur, M Copeman, K Lynch, NC Tebbutt

CANCER CHEMOTHERAPY AND PHARMACOLOGY | SPRINGER | Published : 2013

Abstract

PURPOSE: Platelet-derived growth factor receptor (PDGFR) inhibition by reducing tumoral interstitial fluid pressure might increase the efficacy of chemotherapy. Imatinib inhibits PDGFR kinase activity at therapeutically relevant doses. This phase I study aimed to assess the maximal tolerated dose (MTD) of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer and to identify pharmacokinetic (PK) interactions and toxicities. METHODS: Eligible patients had measurable disease and adequate organ function. On day-14, patients commenced imatinib daily plus bevacizumab (5 mg/kg/2 weekly). Two weeks later (day 1), patients were also treated with full dose mFOLF..

View full abstract

Grants

Funding Acknowledgements

I would like to thank the analytical staff of the Translational Research Laboratory, Peter MacCallum Cancer Centre for the oxaliplatin and 5FU analysis. I would also thank the analytical staff of the Royal Adelaide Hospital for the imatinib analysis. This work was supported by funding from Novartis Australia.J. Zalcberg: Travel and Research Funding and Honorarium; K. Lynch: Previous employee of Novartis Australia; M. Copeman: Employee of Novartis Australia, G. McArthur: Research funding from Novartis; M. Michael, M. Jefford, M. Gouillou, P. Gibbs, L. Lipton, N. C. Tebbutt: No conflict of interest.